Get the Stockscreener App
0.49
2.00%
-0.01
After Hours:
.47
-0.02
-4.08%
VolitionRX Ltd stock is traded at $0.49, with a volume of 169.54K.
It is down -2.00% in the last 24 hours and down -14.05% over the past month.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
See More
Previous Close:
$0.50
Open:
$0.5025
24h Volume:
169.54K
Relative Volume:
1.05
Market Cap:
$49.38M
Revenue:
$1.29M
Net Income/Loss:
$-29.87M
P/E Ratio:
-1.3611
EPS:
-0.36
Net Cash Flow:
$-14.70M
1W Performance:
+1.24%
1M Performance:
-14.05%
6M Performance:
-32.85%
1Y Performance:
-17.52%
1-Day Range:
$0.46
$0.51
1-Week Range:
$0.45
$0.54
52-Week Range:
$0.42
$1.02
VolitionRX Ltd Stock (VNRX) Company Profile
Name
VolitionRX Ltd
Sector
Industry
Phone
646 650 1351
Address
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.49 | 49.38M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
427.50 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
186.83 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
411.49 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
102.48 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
143.91 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | H.C. Wainwright | Buy |
| Feb-01-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-17-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-10-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-18 | Initiated | Maxim Group | Buy |
| May-14-18 | Reiterated | The Benchmark Company | Buy |
| Sep-07-16 | Reiterated | Rodman & Renshaw | Buy |
| Feb-01-16 | Initiated | Rodman & Renshaw | Buy |
View All
VolitionRX Ltd Stock (VNRX) Latest News
VolitionRX Ltd (AMEX: VNRX): An Enticing Stock To Watch - stocksregister.com
H.C. Wainwright maintains buy on VolitionRX with $2.50 target By Investing.com - Investing.com South Africa
VolitionRx (NYSE:VNRX) Coverage Initiated at HC Wainwright - The AM Reporter
VolitionRX stock holds as Benchmark maintains rating - Investing.com Australia
What is HC Wainwright’s Estimate for VolitionRx Q1 Earnings? - Defense World
VolitionRx (NYSE:VNRX) Now Covered by Analysts at HC Wainwright - Defense World
VolitionRX stock holds as Benchmark maintains rating By Investing.com - Investing.com South Africa
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
VolitionRx Moves to Register Warrant Shares on New Form By Investing.com - Investing.com South Africa
VolitionRx Moves to Register Warrant Shares on New Form - Investing.com
VolitionRx Limited (AMEX:VNRX) Q4 2024 Earnings Call Transcript - Insider Monkey
VolitionRx Ltd. Earnings Call Highlights Growth and Challenges - TipRanks
VolitionRX Ltd (VNRX) Reports Q4 EPS of -0.06, Revenue Surges to $1.2 Million, Exceeding Estimates - GuruFocus
VolitionRx (VNRX) Sees Strong Growth with Doubling of Nu.Q Vet T - GuruFocus
Earnings call transcript: VolitionRx revenue beats forecast in Q4 2024 - Investing.com India
VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances - Yahoo Finance
VolitionRx Limited Reports Strong 2024 Financial Results - TipRanks
Volitionrx Ltd earnings missed, revenue fell short of estimates - Investing.com
Volitionrx Ltd earnings missed, revenue fell short of estimates By Investing.com - Investing.com South Africa
Earnings call transcript: VolitionRx revenue beats forecast in Q4 2024 By Investing.com - Investing.com UK
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update - Financial Times
A Look Ahead: VolitionRX's Earnings Forecast - Benzinga
Volition Announces Two Poster Presentations At Esmo's European Lung Cancer Congress 2025 - MarketScreener
Volitionrx director Innes buys $99,999 in common stock By Investing.com - Investing.com Canada
VolitionRx CEO Cameron Reynolds acquires $99,999 in stock - Investing.com
Volitionrx director Innes buys $99,999 in common stock - Investing.com
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025 - Yahoo Finance
VolitionRx secures up to $2.3 million in direct offering By Investing.com - Investing.com South Africa
VolitionRx secures up to $2.3 million in direct offering - Investing.com India
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering - Marketscreener.com
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update - Yahoo Finance
D. Boral Capital Reaffirms “Buy” Rating for VolitionRx (NYSE:VNRX) - Defense World
VolitionRX Reports Positive Results of Automated Nu.Q Cancer Immunoassay Test in Development - Marketscreener.com
VolitionRx reports results from Nu.Q Cancer test - TipRanks
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry - Yahoo Finance
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer - Yahoo Finance
Volitionrx announces pricing of public offering of 3.77 mln shares - Reuters
Volition Proudly Sponsors the 44th ISICEM Congress - Yahoo Finance
VolitionRx (VNRX) Projected to Post Quarterly Earnings on Monday - Defense World
D. Boral Capital Reiterates Buy Rating for VolitionRx (NYSE:VNRX) - Defense World
VolitionRx expands cancer test deal with Fujifilm Vet Systems By Investing.com - Investing.com Australia
VolitionRx extends Nu.Q Vet Cancer Test automation agreement with Fujifilm - TipRanks
Volition Signs First Ever Nu.Q Vet Cancer Test Automation Agreement With Fujifilm Vet Systems - Marketscreener.com
VolitionRx expands cancer test deal with Fujifilm Vet Systems - Investing.com India
VolitionRx Signs Canine Cancer Test Automation Deal With Fujifilm Vet Systems -March 13, 2025 at 09:07 am EDT - Marketscreener.com
Volition's Game-Changing Cancer Test for Dogs Goes Automated with Fujifilm Deal - StockTitan
StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - Defense World
VNRX: Additional clinical papers & company webinars provide insights to Volition’s progress. Nu.Q Discover biomarkers selected for clinical trial. Management continues to focus on signing licensing deals for Capture-PCR & Nu.Q NETs - Yahoo Finance
VolitionRx’s (VNRX) Buy Rating Reaffirmed at D. Boral Capital - Defense World
VolitionRX Ltd Stock (VNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
VolitionRX Ltd Stock (VNRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Innes Guy Archibald | Director |
Mar 26 '25 |
Buy |
0.55 |
181,818 |
100,000 |
868,689 |
| Innes Guy Archibald | Director |
Dec 09 '24 |
Buy |
0.57 |
174,764 |
100,000 |
617,085 |
| STILL TIMOTHY I | Director |
Dec 09 '24 |
Buy |
0.57 |
87,382 |
50,000 |
1,487,382 |
| Micallef Jacob Vincent | Chief Scientific Officer |
Dec 09 '24 |
Buy |
0.57 |
43,691 |
25,000 |
394,352 |
| Reynolds Cameron John | President and CEO |
Dec 09 '24 |
Buy |
0.57 |
139,811 |
80,000 |
2,117,404 |
| Innes Guy Archibald | Director |
Aug 20 '24 |
Buy |
0.67 |
150,000 |
100,500 |
406,683 |
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):